-
Something wrong with this record ?
Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms
J. Kissova, A. Bulikova, P. Ovesna, L. Bourkova, M. Penka,
Language English Country Japan
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
ProQuest Central
from 2001-01-01 to 1 year ago
Medline Complete (EBSCOhost)
from 2011-01-01 to 1 year ago
Nursing & Allied Health Database (ProQuest)
from 2001-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2001-01-01 to 1 year ago
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Quinazolines therapeutic use MeSH
- Adult MeSH
- Platelet Aggregation Inhibitors therapeutic use MeSH
- Janus Kinase 2 genetics MeSH
- Middle Aged MeSH
- Humans MeSH
- Mutation MeSH
- Myeloproliferative Disorders complications diagnosis genetics MeSH
- Risk Factors MeSH
- Aged MeSH
- Mean Platelet Volume * MeSH
- Case-Control Studies MeSH
- Blood Platelets * metabolism pathology MeSH
- Thrombosis blood drug therapy etiology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc15031853
- 003
- CZ-PrNML
- 005
- 20151013103745.0
- 007
- ta
- 008
- 151005s2014 ja f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s12185-014-1673-0 $2 doi
- 035 __
- $a (PubMed)25227185
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ja
- 100 1_
- $a Kissova, Jarmila $u Department of Haematology, University Hospital Brno, Jihlavska 20, 625 00, Brno, Czech Republic, jkissova@fnbrno.cz.
- 245 10
- $a Increased mean platelet volume and immature platelet fraction as potential predictors of thrombotic complications in BCR/ABL-negative myeloproliferative neoplasms / $c J. Kissova, A. Bulikova, P. Ovesna, L. Bourkova, M. Penka,
- 520 9_
- $a BCR/ABL-negative myeloproliferative neoplasms (MPNs) are considered to be acquired thrombophilic conditions. Persistently enhanced platelet activation has been described in polycythaemia vera and essential thrombocythaemia (ET), and shown to contribute to a higher risk of arterial and venous thrombotic complications. Recent studies have shown that mean platelet volume (MPV) and immature platelet fraction (IPF) can serve as useful markers of platelet activation and increased risk of thrombosis. The aim of the present study was to investigate the relationship between these parameters and thrombotic events in BCR/ABL-negative MPN. MPV values in patients with BCR/ABL-negative MPN were significantly higher than MPV values of healthy individuals (P < 0.001). No significant difference in MPV or IPF was observed between groups of patients with and without thrombotic complications (P = 0.441; P = 0.110); the difference in IPF values was close to the significance level for patients with ET (P = 0.073). Higher values of IPF were more frequently detected in patients with JAK2 V617F positivity (P = 0.030). These patients had higher MPV more frequently than others, and this difference was close to the significance level (P = 0.056). Further studies should validate the use of platelet parameters to identify patients at high risk.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 12
- $a trombocyty $x metabolismus $x patologie $7 D001792
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a bcr-abl fúzní proteiny $x genetika $7 D016044
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Janus kinasa 2 $x genetika $7 D053614
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a střední objem trombocytu $7 D063847
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a mutace $7 D009154
- 650 _2
- $a myeloproliferativní poruchy $x komplikace $x diagnóza $x genetika $7 D009196
- 650 _2
- $a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
- 650 _2
- $a chinazoliny $x terapeutické užití $7 D011799
- 650 _2
- $a rizikové faktory $7 D012307
- 650 _2
- $a trombóza $x krev $x farmakoterapie $x etiologie $7 D013927
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Bulikova, Alena
- 700 1_
- $a Ovesna, Petra
- 700 1_
- $a Bourkova, Ludmila
- 700 1_
- $a Penka, Miroslav
- 773 0_
- $w MED00002329 $t International journal of hematology $x 1865-3774 $g Roč. 100, č. 5 (2014), s. 429-36
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/25227185 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20151005 $b ABA008
- 991 __
- $a 20151013103935 $b ABA008
- 999 __
- $a ok $b bmc $g 1092729 $s 914979
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2014 $b 100 $c 5 $d 429-36 $e 20140917 $i 1865-3774 $m International journal of hematology $n Int J Hematol $x MED00002329
- LZP __
- $a Pubmed-20151005